查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961157

细胞转染市场－全球产业规模、份额、趋势、机会和预测：按方法、最终用户、地区和竞争对手划分，2021-2031年

Cell Transfection Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Method, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球细胞转染市场预计将从 2025 年的 20.8 亿美元成长到 2031 年的 34.9 亿美元，复合年增长率为 9.01%。

该市场涵盖了多种技术、试剂和设备，用于将外来性核酸导入真核细胞，以达到基因表现修饰和蛋白质生产等目的。该领域的成长主要得益于生物製药研发投资的激增以及细胞和基因治疗生产业务的扩张。根据美国细胞与基因治疗学会 (ASGCT) 预测，2024 年该领域的研究活动将显着增加，其年会上提交的科学摘要数量将比前一年增加 12%。这项数据凸显了对高效转染调查方法日益增长的需求，以支持不断增长的临床前和转化研究。

市场概览
预测期 2027-2031
市场规模：2025年 20.8亿美元
市场规模：2031年 34.9亿美元
复合年增长率：2026-2031年 9.01%
成长最快的细分市场 电穿孔
最大的市场 北美洲

儘管市场呈现成长态势，但标准转染方法固有的细胞毒性和效率差异性仍构成重大挑战。许多化学试剂和物理转染技术已知会诱导细胞压力和细胞死亡，尤其是在敏感的原代细胞中，这会损害实验数据的完整性，并限制这些工具在先进治疗研发中的实际应用。因此，如何克服这些限制——在确保基因转移成功的同时维持细胞活力——仍然是致力于优化先进治疗流程的研究人员和生产商面临的关键挑战。

市场驱动因素

全球细胞和基因治疗研发管线的快速扩张是细胞转染市场的主要驱动力，也因此迫切需要能够有效递送遗传物质的技术。随着治疗倡议从临床前阶段推进到商业化生产阶段，生物製药开发商需要可靠的转染方法来确保病毒载体生产和细胞药物设计的高度一致性。大量候选药物的研发为这项活跃的研发进程提供了支持。根据美国细胞和基因治疗学会 (ASGCT) 和 Citeline 于 2024 年 4 月发布的报告，全球有超过 4000 种基因、细胞和 RNA 疗法正在研发中。因此，不断扩展的研发管线推动了各种递送流程所需的关键转染试剂和电穿孔设备的持续供应。

同时，医药和生技领域研发投入的增加显着推动了市场成长，主要企业积极投资建设新设施，以增强其药物发现和生产能力。这些投资日益集中在利用转染技术进行重组蛋白合成和基因组药物开发的先进製造中心。例如，2024年10月，礼来公司宣布投资45亿美元建立礼来医药铸造厂（Lilly Medicine Foundry），该厂将整合研发和先进製造技术。这种基础设施扩张的趋势十分普遍。 DCAT价值链洞察公司在2024年12月发布的报告显示，诺和诺德公司当年投资约68亿美元用于扩展其全球生产网络，凸显了对生物製程技术的工业规模需求。

市场挑战

与标准转染技术相关的细胞毒性和效率差异是阻碍全球细胞转染市场扩张的重大障碍。这些技术难题导致基因传递的异质性和细胞活力的降低，显着增加了先进治疗药物生产过程中批次缺陷的风险。当转染试剂引起细胞毒性或未能达到所需的效力标准时，製造商将面临高比例的不合格产品，造成巨大的经济损失和生产週期延长。这种不可预测性是业务扩张的主要障碍，迫使企业将过多的资源投入到品管和製程改进，而非市场成长。

例如，在转染过程中维持细胞完整性的挑战是造成生产过程中损失的主要原因之一。根据美国临床肿瘤学会2024年发布的商业化阶段细胞疗法生产数据，某些基因修饰疗法的不合格率高达约28%，其中细胞活力低被认为是造成这些失败的主要原因。如此高的失败率凸显了目前转染方法固有的操作不稳定性，限制了该行业可靠地满足生物製药产品激增需求的能力。

市场趋势

在市场上，非病毒脂质体奈米颗粒载体的应用日益受到重视，以解决病毒递送系统固有的安全隐患和生产瓶颈。生物製药开发公司正在迅速整合这些合成载体，与传统病毒载体相比，它们具有更低的免疫抗原性，并能更有效率地放大mRNA和基因编辑有效载荷。这种向先进非病毒机制的策略转变，正推动着专注于下一代递送技术的公司获得大量资本投资。例如，2024年3月，Capstan Therapeutics公司资金筹措，用于进一步开发其专有的标靶化脂质奈米颗粒（tLNP）平台，以进行体内免疫细胞修饰。这凸显了业界对基于脂质的系统作为未来安全递送复杂基因疗法标准的信心。

同时，符合cGMP规范的可扩展电穿孔平台正成为主流，旨在维持高转染效率的同时，满足商业化生产中严格的监管标准。随着治疗计画从药物发现推进到临床应用，企业正逐步以自动化物理性递送系统取代人工操作。这确保了即使在大规模生产中也能保持性能稳定，并降低了批次间差异的风险。这种对检验的高通量仪器的日益依赖，得益于业界关键技术的应用。例如，2024年5月，MaxCyte与Legend Biotech达成了一项策略平台授权合约，授权后者使用MaxCyte的流式电穿孔技术开发一系列细胞疗法。此类协议凸显了标准化、自动化电穿孔工作流程在保障先进细胞疗法供应链方面发挥的关键作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球细胞转染市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 方法（电穿孔法、脂质体转染法、磷酸钙法、病毒载体法、其他）
    • 按最终用户（学术研究机构、製药和生物技术公司、合约研究组织等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美细胞转染市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲细胞转染市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区细胞转染市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲细胞转染市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美细胞转染市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球细胞转染市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Thermo Fisher Scientific, Inc.
  • Promega Corporation
  • Lonza Group AG
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories Inc.
  • Merck KGaA,
  • OriGene Technologies, Inc.
  • MaxCyte, Inc.
  • Polyplus-transfection SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23886

The Global Cell Transfection Market is projected to expand from USD 2.08 Billion in 2025 to USD 3.49 Billion by 2031, reflecting a compound annual growth rate of 9.01%. This market encompasses the diverse array of technologies, reagents, and instruments employed to deliver exogenous nucleic acids into eukaryotic cells for the purpose of modifying gene expression and producing proteins. The sector's growth is fundamentally underpinned by a surge in biopharmaceutical research investments and the operational scaling of cell and gene therapy manufacturing. According to the American Society of Gene & Cell Therapy, research activity in this domain intensified significantly in 2024, as demonstrated by a 12% rise in scientific abstracts presented at their annual meeting compared to the prior year. This statistic highlights the escalating necessity for effective transfection methodologies to sustain an increasing volume of pre-clinical and translational research.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.08 Billion
Market Size 2031USD 3.49 Billion
CAGR 2026-20319.01%
Fastest Growing SegmentElectroporation
Largest MarketNorth America

Despite this growth trajectory, the market encounters substantial hurdles related to the cytotoxicity and inconsistent efficiency characteristic of standard transfection methods. Many chemical reagents and physical delivery techniques are known to induce cellular stress or cell death, particularly within sensitive primary cells, which compromises the integrity of experimental data and limits the practical application of these tools in advanced therapeutic development. Consequently, addressing these limitations to preserve cell viability while ensuring successful gene delivery remains a critical concern for researchers and manufacturers aiming to optimize advanced therapeutic workflows.

Market Driver

The rapid broadening of the global cell and gene therapy pipeline acts as a primary catalyst for the cell transfection market, generating an urgent need for technologies that enable the effective delivery of genetic material. As therapeutic initiatives progress from preclinical stages to commercial-scale manufacturing, biopharmaceutical developers require reliable transfection methods to produce viral vectors and engineer cell-based medicines with high consistency. This intense development activity is underscored by the sheer volume of active candidates; according to an April 2024 report by the American Society of Gene & Cell Therapy and Citeline, there were over 4,000 gene, cell, and RNA therapies in development worldwide. Consequently, this expanding pipeline propels the sustained procurement of essential transfection reagents and electroporation instruments required for diverse delivery workflows.

Simultaneously, escalating investment in pharmaceutical and biotechnology R&D is significantly reinforcing market growth, with major industry leaders aggressively funding new facilities to bolster drug discovery and production capabilities. These financial commitments are increasingly focused on advanced manufacturing centers that employ transfection for recombinant protein synthesis and genomic medicine development. For instance, Eli Lilly announced a $4.5 billion investment in October 2024 to create the Lilly Medicine Foundry, a facility aimed at integrating research with advanced manufacturing. This trend of infrastructure expansion is widespread; in December 2024, DCAT Value Chain Insights reported that Novo Nordisk invested approximately $6.8 billion cumulatively that year to enlarge its global production network, highlighting the industrial-scale demand for bioprocessing technologies.

Market Challenge

The cytotoxicity and variable efficiency linked to standard transfection techniques represent a critical impediment that directly obstructs the expansion of the Global Cell Transfection Market. These technical shortcomings lead to inconsistent gene transfer and diminished cellular viability, which significantly elevates the risk of batch failure during the manufacturing of advanced therapies. When transfection reagents cause cellular toxicity or fail to achieve required potency standards, manufacturers face high rates of out-of-specification products, resulting in substantial financial setbacks and prolonged production schedules. This unpredictability creates a formidable barrier to scaling operations, compelling companies to divert excessive resources toward quality control and process repetition rather than market growth.

For example, the challenge of maintaining cell health during the transfection process is a leading cause of manufacturing attrition. Data from commercial-stage cell therapy production, as reported by the American Society of Clinical Oncology in 2024, indicated that out-of-specification rates for certain gene-modified therapies reached approximately 28%, with low cellular viability pinpointed as a primary driver of these failures. Such high failure rates highlight the operational volatility introduced by current transfection methods, thereby restricting the industry's ability to reliably satisfy the surging demand for biopharmaceutical products.

Market Trends

The market is increasingly prioritizing the adoption of non-viral lipid nanoparticle vectors to address the safety concerns and manufacturing bottlenecks inherent in viral delivery systems. Biopharmaceutical developers are rapidly integrating these synthetic carriers because they offer reduced immunogenicity and streamlined scalability for delivering mRNA and gene-editing payloads compared to traditional viral vectors. This strategic pivot toward advanced non-viral mechanisms is fueling substantial capital investment in companies focused on next-generation delivery technologies. For instance, Capstan Therapeutics secured $175 million in Series B financing in March 2024 specifically to further its proprietary targeted lipid nanoparticle (tLNP) platform for the in vivo engineering of immune cells, underscoring the industry's confidence in lipid-based systems as the future standard for the safe administration of complex genetic medicines.

Concurrently, there is a definitive transition toward scalable cGMP-compliant electroporation platforms engineered to maintain high transfection efficiency while satisfying rigorous regulatory standards for commercial manufacturing. As therapeutic programs advance from discovery to clinical application, firms are replacing manual techniques with automated physical delivery systems that ensure consistent performance across large production volumes, thereby mitigating the risk of batch variability. This growing reliance on validated, high-throughput instrumentation is evidenced by major technology adoptions within the sector; for example, MaxCyte entered into a strategic platform license with Legend Biotech in May 2024, granting rights to use its Flow Electroporation technology for the development of a diverse cell therapy portfolio. Such agreements emphasize the critical role of standardized, automated electroporation workflows in securing the supply chain for advanced cellular therapies.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Promega Corporation
  • Lonza Group AG
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories Inc.
  • Merck KGaA,
  • OriGene Technologies, Inc.
  • MaxCyte, Inc.
  • Polyplus-transfection SA

Report Scope

In this report, the Global Cell Transfection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Transfection Market, By Method

  • Electroporation
  • Lipofection
  • Calcium Phosphate
  • Viral Transfection
  • Others

Cell Transfection Market, By End User

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Others

Cell Transfection Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Transfection Market.

Available Customizations:

Global Cell Transfection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Transfection Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Method (Electroporation, Lipofection, Calcium Phosphate, Viral Transfection, Others)
    • 5.2.2. By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cell Transfection Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Transfection Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Method
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Cell Transfection Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Method
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Cell Transfection Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Method
        • 6.3.3.2.2. By End User

7. Europe Cell Transfection Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Transfection Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By End User
    • 7.3.2. France Cell Transfection Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Cell Transfection Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Cell Transfection Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Method
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Cell Transfection Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Method
        • 7.3.5.2.2. By End User

8. Asia Pacific Cell Transfection Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell Transfection Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By End User
    • 8.3.2. India Cell Transfection Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Cell Transfection Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Cell Transfection Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Cell Transfection Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By End User

9. Middle East & Africa Cell Transfection Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell Transfection Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Cell Transfection Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Cell Transfection Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By End User

10. South America Cell Transfection Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell Transfection Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Cell Transfection Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Cell Transfection Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell Transfection Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Promega Corporation
  • 15.3. Lonza Group AG
  • 15.4. QIAGEN NV
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Bio-Rad Laboratories Inc.
  • 15.7. Merck KGaA,
  • 15.8. OriGene Technologies, Inc.
  • 15.9. MaxCyte, Inc.
  • 15.10. Polyplus-transfection SA

16. Strategic Recommendations

17. About Us & Disclaimer